Complex Molecular Etiology and Cellular Landscape of Hip Osteoarthritis

NCT05278520 | Recruiting

• 1 other identifier: 2022OASEQ
• Study Type: observational
• Target: 110
• Locations: 1 country
• Sites: 4

Brief Summary

The purpose of this study is to cast light on the highly complex etiology and cellular landscape of hip osteoarthritis by utilising single-cell and spatial omics.

Conditions

Osteoarthritis, Hip; Rheumatoid Arthritis

Keywords

Single-cell RNA sequencing; Spatial transcriptomics; Osteoarthritis; Rheumatoid arthritis; Spatial proteomics

Outcome Measures

Primary Outcomes (5)

• Characterization of cell populations in OA

  Characterization of cell populations found in different synovial tissues and blood derived samples of OA patients utilising single-cell RNA sequencing solutions.

  Starting during the first quarter of 2025, ending by the last quarter of 2026.

• Comparison of cell populations between OA cases and controls

  The investigators will determine how the cell composition differs between arthritic and corresponding non-arthritic tissues utilising single-cell RNA sequencing solutions.

  Starting during the first quarter of 2025, ending by the last quarter of 2026.

• Cellular landscape in OA

  The investigators will map the transcriptional, regulatory and protein landscape of OA at single-cell and tissue (spatial) level.

  Starting during the last quarter of 2024, ending by the last quarter of 2026.

• Key molecular pathways of OA

  The investigators will determine what are the key molecular pathways activated in OA.

  Starting during the last quarter of 2025, ending by the last quarter of 2027.

• Comparison of disease mechanisms between RA and OA

  In the Rheumatoid sub-study the investigators will explore the differences in the disease mechanisms between OA and RA by comparing synovial tissues and peripheral blood sample constituents.

  Starting during the last quarter of 2024, ending by the last quarter of 2028.

Secondary Outcomes (2)

• Biomarkers for OA

  Starting during the second half of 2026, ending by the last quarter of 2028.

• OA endotypes

  Starting during the first half of 2025, ending by the second half of 2027.

Study Arms (3)

OA cases

Fifty adult patients who have hip osteoarthritis.

Procedure: Total hip arthroplasty

RA cases

Forty adult patients who have rheumatoid arthritis in the hip joint.

Procedure: Total hip arthroplasty

Non-arthritic controls

Twenty adult patients who go through trauma-based emergency total hip arthroplasty and do not have arthritis.

Procedure: Total hip arthroplasty

Interventions

Total hip arthroplasty PROCEDURE

Hip joint replacement surgery. Elective for RA and OA cases.

Non-arthritic controls; OA cases; RA cases

Eligibility Criteria

• Age: 18 Years - 74 Years
• Sex: all
• Healthy Volunteers: Yes
• Age Groups: Adult (18-64), Older Adult (65+)
• Sampling Method: Non-Probability Sample

Study Population

Adult patients of the HUS (Joint Authority of the Helsinki and Uusimaa Hospital District) Center of Arthroplasty and the Orto Surgical Hospital of Turku University.

You may qualify if:

• Cases: Adult patients with osteoarthritis in the hip joint and who are going through an elective total hip arthroplasty.
• Controls: Non-arthritis adult patients who are going through a trauma-based emergency total hip arthroplasty.
• \----
• Adult patients with rheumatoid arthritis in the hip joint and who are going through an elective total hip arthroplasty.
• \----

You may not qualify if:

• The body mass index must be below 35
• Age \< 18 or \> 74
• The OA patients may not have diabetes, rheumatoid arthritis (RA), or metabolic syndrome.

Sponsors & Collaborators

• University of Turku: lead
• Turku University Hospital: collaborator
• Hospital District of Helsinki and Uusimaa: collaborator

Study Sites (4)

PET-centre, University of Turku

Turku, Southwest Finland, Finland

ACTIVE NOT RECRUITING

Turku Bioscience, University of Turku

Turku, Southwest Finland, Finland

ACTIVE NOT RECRUITING

Turku University Hospital

Turku, Southwest Finland, Finland

RECRUITING

Helsinki University Hospital

Espoo, Uusimaa, Finland

RECRUITING

Related Publications (1)

• Rydgren E, Kotilainen SK, Piipponen M, Lönnberg T, Mikkola L. COMPARISON OF TWO HIGH-RESOLUTION SPATIAL TRANSCRIPTOMICS TECHNOLOGIES TO STUDY SYNOVIAL IMMUNE INFILTRATION IN OSTEOARTHRITIS AND RHEUMATOID ARTHRITIS Osteoarthritis and Cartilage, Volume 33, Issue 6, 2025, page 816. https://doi.org/10.1016/j.joca.2025.03.079

  BACKGROUND

Biospecimen

Retention: SAMPLES WITH DNA

Hip joint synovial tissues and bone, peripheral blood mononuclear cells, serum, plasma, and whole blood.

MeSH Terms

Conditions

Osteoarthritis, Hip; Arthritis, Rheumatoid; Osteoarthritis

Interventions

Arthroplasty, Replacement, Hip

Condition Hierarchy (Ancestors)

Arthritis; Joint Diseases; Musculoskeletal Diseases; Rheumatic Diseases; Connective Tissue Diseases; Skin and Connective Tissue Diseases; Autoimmune Diseases; Immune System Diseases

Intervention Hierarchy (Ancestors)

Arthroplasty, Replacement; Arthroplasty; Orthopedic Procedures; Surgical Procedures, Operative; Plastic Surgery Procedures; Prosthesis Implantation

Study Officials

• Lea Mikkola, PhD

  Turku Bioscience, University of Turku

  PRINCIPAL INVESTIGATOR

Central Study Contacts

Lea Mikkola, PhD

CONTACT

+358404143300; limikk@utu.fi

Study Design

• Study Type: observational
• Observational Model: CASE CONTROL
• Time Perspective: CROSS SECTIONAL
• Sponsor Type: OTHER
• Responsible Party: PRINCIPAL INVESTIGATOR
• PI Title: Principal Investigator

Study Record Dates

• First Submitted: March 3, 2022
• First Posted: March 14, 2022
• Study Start: January 11, 2023
• Primary Completion (Estimated): December 1, 2028
• Study Completion (Estimated): December 1, 2028
• Last Updated: August 24, 2025

Record last verified: 2025-08

Data Sharing

• IPD Sharing: Will not share

Locations

FI (4)